Table 3. Prognostic value of Rad51 in NSCLC patients by univariate analysis (log-rank test).

Rad51 expression	Patients (cases)	Mean survival (months)	Median survival (months)	5-year survival (%)	P-value
Total
Low-level expression	240	61	68	50.3	<0.0001
High-level expression	100	38	19	24.9
Cell type
Squamous carcinoma
Low-level expression	85	68	78	61.3	<0.0001
High-level expression	32	28	17	18.8
Adenocarcinoma
Low-level expression	116	54	37	44.8	0.0423
High-level expression	53	42	24	28.3
Clinical stage
Stage I
Low-level expression	71	82	n.r.a	75.7	0.0072
High-level expression	24	49	48	40.9
Stage II
Low-level expression	56	63	n.r.a	60.8	0.0041
High-level expression	24	39	17	37.5
Stage III
Low-level expression	99	41	26	30.0	0.0016
High-level expression	45	21	17	7.4
Stage IV
Low-level expression	14	32	26	26.8	0.6229
High-level expression	7	35	7	28.6

^an.r.=not reached.